CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
AIN457 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00685399
NCT00685399Phase 2Completed
CompareCT.gov

An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis

Novartis Pharmaceuticals·interventional·Posted May 28, 2008·Updated Jul 17, 2017

In Brief

A Phase 2 clinical trial evaluating AIN457 and AIN 457 for Non-infectious Uveitis. Completed, enrolled 76 participants across 23 sites in 2 countries.

Detailed Summary

This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-infectious Uveitis
CountriesGermany, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 28, 2008
Enrollment StartJun 1, 2008
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.1 years ago

Interventions

AIN457drug

AIN457 subcutaneous dose

AIN 457drug

AIN457 low dose (i.v)

AIN457drug

AIN457 high dose (i.v)